Navigation Links
Nanotrope, Inc. Receives Patent on New Diagnostic Test for Influenza and Other Viral Infections
Date:11/17/2010

SAN DIEGO, Nov. 17, 2010 /PRNewswire/ -- Nanotrope, Inc. announced today that it has been issued United States patent #7,829,272 covering its ground-breaking diagnostic test for influenza and other viral infections. The patent describes Nanotrope's cellular mimic technology that creates an artificial "cell" engineered with specific membrane compositions and surface receptors which stimulate the virus into infecting the mimic as it would a normal host cell.  Once the cell mimic is infected, viral genome sequences are detected by multi-color fluorescence providing both viral typing and sub-typing capabilities. The sensitivity of the test is comparable to PCR (polymerase chain reaction) detection limits but in a faster, less expensive and simpler format.

The Nanotrope assay may be used to identify any envelope virus, a class of viruses that includes such important infectious disease targets as influenza where the assay can distinguish between seasonal, swine, and pandemic flu strains, RSV, a serious lung disease in young children, West Nile virus, SARS, measles, and rabies. For contagious viral infections, it is important to identify the virus early in the course of the infection so that sick patients may be isolated and properly treated. The high sensitivity, short time to result, and sub-typing capability of the new assay makes it well-suited for hospital and clinical labs where the time to diagnosis is important, as well as for global surveillance for vaccine development.

Nanotrope is a privately held nano-biomaterials company with a focus on developing new products for the pharmaceutical and diagnostic industries. Its expertise in particle technology has enabled a diverse portfolio of intellectual property. The company is actively looking for partners to commercialize its diagnostics technology. Inquiries may be directed to Dr. Donald Ackley at 858-847-7300, don@nanotrope.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dr. Donald E Ackley

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=99308


'/>"/>
SOURCE Nanotrope, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
2. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
8. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
9. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):